Insider Transactions in Q2 2021 at Spring Works Therapeutics, Inc. (SWTX)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2021
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
6,502
-0.11%
|
$552,670
$85.17 P/Share
|
|
Jun 25
2021
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
22,334
-0.37%
|
$1,898,390
$85.14 P/Share
|
|
Jun 24
2021
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
34,200
-0.56%
|
$2,907,000
$85.22 P/Share
|
|
Jun 23
2021
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
100
-0.0%
|
$8,500
$85.0 P/Share
|
|
Jun 10
2021
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
30,852
-0.5%
|
$2,622,420
$85.09 P/Share
|
|
Jun 09
2021
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,049
-0.08%
|
$429,165
$85.33 P/Share
|
|
Jun 08
2021
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
42,633
-0.69%
|
$3,623,805
$85.37 P/Share
|
|
Jun 07
2021
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
371
-0.01%
|
$31,164
$84.9 P/Share
|
|
Jun 01
2021
|
Michael F. Burgess Head of Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+50.0%
|
-
|
|
May 20
2021
|
Jeffrey Lawrence Schwartz Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,106
+50.0%
|
-
|
|
May 20
2021
|
Stephen P Squinto Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,106
+0.86%
|
-
|
|
May 20
2021
|
Daniel Lynch Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,106
+0.38%
|
-
|
|
May 20
2021
|
Freda C Lewis Hall Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,106
+4.2%
|
-
|
|
May 20
2021
|
Julie Hambleton Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,106
+15.58%
|
-
|
|
May 20
2021
|
Alan Fuhrman Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,106
+4.2%
|
-
|
|
Apr 28
2021
|
Stephen P Squinto Director |
SELL
Open market or private sale
|
Direct |
19,231
-13.27%
|
$1,461,556
$76.2 P/Share
|
|
Apr 27
2021
|
Stephen P Squinto Director |
SELL
Open market or private sale
|
Direct |
201
-0.14%
|
$15,075
$75.05 P/Share
|
|
Apr 20
2021
|
Saqib Islam Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
24,075
-2.65%
|
$1,588,950
$66.39 P/Share
|
|
Apr 19
2021
|
Saqib Islam Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
38,425
-4.06%
|
$2,651,325
$69.04 P/Share
|
|
Apr 15
2021
|
Stephen P Squinto Director |
SELL
Open market or private sale
|
Direct |
1,057
-0.72%
|
$79,275
$75.01 P/Share
|
|
Apr 14
2021
|
Stephen P Squinto Director |
SELL
Open market or private sale
|
Direct |
511
-0.35%
|
$38,325
$75.08 P/Share
|
|
Apr 13
2021
|
L. Mary Smith Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-5.63%
|
$680,000
$68.07 P/Share
|
|
Apr 13
2021
|
L. Mary Smith Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.33%
|
$20,000
$2.3 P/Share
|
|
Apr 01
2021
|
Bhavesh Ashar Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+50.0%
|
-
|